This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00028/identifier/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00028/identifier/national-drug-code-directory/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n4http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00028/identifier/genbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00028/identifier/uniprotkb/
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n20http://www.drugs.com/cdi/
n9http://www.rxlist.com/cgi/generic2/
n7http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00028/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00028
rdf:type
n5:Drug
n5:description
Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.
n5:generalReferences
# Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1):9-15. Epub 2010 Dec 9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20970960 # Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17911465 # Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006 Sep;253 Suppl 5:V18-24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16998749 # Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12032582 # http://www.path.cam.ac.uk/~mrc7/lecturenotes/handout1a.pdf
n5:group
investigational approved
n5:halfLife
>20 hours (mammalian reticulocytes, in vitro).
n5:indication
IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases.
owl:sameAs
n4:DB00028 n17:DB00028
dcterms:title
Intravenous Immunoglobulin
adms:identifier
n12:DB00028 n13:67467-843-01 n14:P01877 n16:J00221 n21:PA164754884
n5:mechanismOfAction
IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.
n5:packager
n10:271B4050-363D-11E5-9242-09173F13E4C5 n10:271B4051-363D-11E5-9242-09173F13E4C5 n10:271B404E-363D-11E5-9242-09173F13E4C5 n10:271B404F-363D-11E5-9242-09173F13E4C5 n10:271B404C-363D-11E5-9242-09173F13E4C5 n10:271B404D-363D-11E5-9242-09173F13E4C5 n10:271B404A-363D-11E5-9242-09173F13E4C5 n10:271B404B-363D-11E5-9242-09173F13E4C5 n10:271B4056-363D-11E5-9242-09173F13E4C5 n10:271B4054-363D-11E5-9242-09173F13E4C5 n10:271B4055-363D-11E5-9242-09173F13E4C5 n10:271B4052-363D-11E5-9242-09173F13E4C5 n10:271B4053-363D-11E5-9242-09173F13E4C5
n5:synonym
Immunoglobulin G Ig alpha-2 chain C region immune globulin
n18:hasAHFSCode
n19:80-04-00
n5:synthesisReference
Wolfgang Stephan, "Production of intravenously applicable native human immune globulin having a normal half-life." U.S. Patent US4082734, issued July, 1970.
foaf:page
n9:baygam.htm n20:immune-globulin-human.html
n5:Molecular-Formula
n7:271B4068-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n7:271B4067-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Various viruses Humans and other mammals Bacteria and protozoa
n5:casRegistryNumber
9007-83-4
n5:category
n5:containedIn
n6:271B4059-363D-11E5-9242-09173F13E4C5 n6:271B405A-363D-11E5-9242-09173F13E4C5 n6:271B4057-363D-11E5-9242-09173F13E4C5 n6:271B4058-363D-11E5-9242-09173F13E4C5 n6:271B4061-363D-11E5-9242-09173F13E4C5 n6:271B4062-363D-11E5-9242-09173F13E4C5 n6:271B405F-363D-11E5-9242-09173F13E4C5 n6:271B4060-363D-11E5-9242-09173F13E4C5 n6:271B405D-363D-11E5-9242-09173F13E4C5 n6:271B405E-363D-11E5-9242-09173F13E4C5 n6:271B405B-363D-11E5-9242-09173F13E4C5 n6:271B405C-363D-11E5-9242-09173F13E4C5 n6:271B4063-363D-11E5-9242-09173F13E4C5
n5:Hydrophobicity
n7:271B4065-363D-11E5-9242-09173F13E4C5
n5:Isoelectric-Point
n7:271B4066-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n7:271B4064-363D-11E5-9242-09173F13E4C5